Forecast

The analysts' average price target is €41.11 (+148.40%). The median is €40.39 (+144.05%).

Buy	4
Hold	0
Sell	0

News Go to news feed

Jade Biosciences advances phase‑III start for JADE101 in IgA nephropathy

At the Citigroup conference, Jade Biosciences presented strong phase‑I biomarkers: JADE101 reduced IgA in healthy volunteers by nearly 70% with effects lasting up to 12 weeks. The company plans to start a phase‑III study in the first half of 2027, without waiting for completion of the ongoing phase‑II data. Jade Bio has $461 million in cash, which management says should fund programs through Q4 2028. Management sees significant market potential (about 170,000 US patients; estimated US market $20 billion) but acknowledges competitive risks from already approved and competing programs. » More on de.investing.com
Jade Biosciences unveils pipeline strategy and backs JADE 101 for IgA nephropathy

Jade Biosciences presented a three‑pillar strategy at the Wells Fargo Healthcare Conference, with lead compound JADE 101 for IgA nephropathy, currently in Phase II and planned to enter Phase III in early 2027. Phase I data in healthy volunteers showed roughly a 70% reduction in serum IgA after an induction dose, lasting up to 12 weeks, and management highlights the planned quarterly maintenance dose as an advantage. The company stresses a cash runway into Q4 2028 but acknowledges a crowded competitive landscape and the need to demonstrate clinical superiority in later studies. Supplemental programs (JADE 201, JADE 301) target B‑cell depletion and dermatomyositis; initial data for both programs are expected in 2027. » More on de.investing.com
Jade Biosciences share falls after heavily discounted placement

Jade Biosciences announces sale of 10 million common shares at $15.00 per share, raising about $150 million before fees and representing a discount of roughly 14.7% to the prior day’s close. The announcement and a 30-day greenshoe option for up to 1.5 million additional shares weighed on premarket trading and led to a roughly 9.3% drop. Jefferies, TD Cowen and UBS are acting as bookrunners; proceeds are intended to fund clinical and preclinical studies and production. A weak market environment amplified selling pressure, but the company stresses the move is to advance the JADE101 pipeline and does not signal financial distress. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2025, Jade Biosciences has already paid €2.11 in dividends. The last payout was in April 2025.

Financials

In the last quarter, Jade Biosciences had revenue of €0 and net profit of -€48.86M

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	-7.89K	-
Net profit	-48.86M	79.22%
EBITDA	-51.61M	89.33%

Fundamentals

Metric	Value
Market capitalization	€1.04B
Number of shares	60.86M
52-week high/low	€24.06 - €5.94
Dividends	No
Beta	1.45
P/E ratio	-7.24
PEG ratio	-0.03
P/B ratio	2.76
P/S ratio	0.00

Company profile

Jade Biosciences, Inc. ist ein Biotechnologieunternehmen, das sich auf die Entwicklung von erstklassigen Therapien konzentriert, um den kritischen ungedeckten Bedarf bei Autoimmunkrankheiten zu decken. Der führende Wirkstoff JADE-001 zielt auf den Anti-A PRoliferation-Inducing Ligand (APRIL)-Signalweg zur Behandlung der Immunglobulin A (IgA)-Nephropathie. JADE-001 wird voraussichtlich in der zweiten Hälfte des Jahres 2025 in die klinische Erprobung eintreten, erste Daten werden für die erste Hälfte des Jahres 2026 erwartet. Die Pipeline des Unternehmens umfasst auch zwei präklinische Antikörperprogramme, JADE-002 und JADE-003.